The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Outcomes of patients with de-novo vs secondary AML treated with CPX-351
Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, presents the results from a study comparing the outcomes of patients with de-novo acute myeloid leukemia (AML) versus those with secondary AML when treated with CPX-351. In this study, patients were divided into five cohorts: no prior history of antecedent hematologic malignancy (AHM) and prior history of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), myeloproliferative neoplasms (MPN), and myelodysplastic syndrome/myeloproliferative neoplasm-unclassifiable (MDS/MPN-U). Overall, the study indicated that patients treated with CPX-351 with no known AHM had a significantly longer overall survival (OS) compared to patients with prior history of CMML or MDS/MPN-U. In contrast, patients with a prior history of MDS did not have a significant decrease in OS. Next-generation sequencing (NGS) analysis showed that clearing mutations at remission did not have an impact on OS and rate of relapse. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
